Because they observed that overall survival (OS) was associated with the mutant allele burden in AML, their data restricted the list of gene mutations, finally including DNMT3A, TET2, ASXL1, RUNX1, and IDH1/2, shown to be useful in MRD-based prognostication in AML [44]. The gene discussed is TET2; the disease is acute myeloid leukemia.